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Introduction
?????? ???????????????????????????? ??? ????? ????? ????????????
discovered the disease in 1906. Dr. Alzheimer had a patient with 
severe memory loss, aphasia, and unnatural behavior who died 
of complications related to her disease. Upon her death, he 
performed an autopsy and noticed two unusual features in the 
??????????????????????????????????????????? ?????????????????
???????????????????????????????????????????????????????????????????
to accurately measure tangles and plaques during the lifetime 
of a patient with the disease; therefore, Alzheimer’s disease is 
diagnosed based on symptoms. The symptoms that are used to 
diagnose Alzheimer’s disease today are much like those of Dr. 
Alzheimer’s original patient. The common symptoms are mem-
ory related issues, trouble with organizational skills, getting lost, 
confusion, and personality changes. Eventually the deterioration 
escalates and the patient may hallucinate, become unable to 
recognize others, and then become unable to talk or eat. Lastly, 
the parts of the brain that directly control living processes are 
affected and death occurs. (National Institute on Aging, 2012)
The progression of Alzheimer’s disease does not happen 
quickly, in fact Alzheimer’s is a very slowly progressing disease, 
???????????????????????????????????????????????????????????????
symptoms and death. This being the case, it is theorized that 
even before symptoms occur, perhaps years prior, there is a 
??????????????????? ??????? ??????????????????????????????????
????????????????????? ???????????????????????????????? ????? ?????
disease. The ability to detect these changes would greatly assist 
?????????????????????????????????????????????????????????????????
(National Institute on Aging, 2012)
Unfortunately, it is not possible with our current level of 
technology to reliably detect the changes in the brain that are 
present in Alzheimer’s, even advanced Alzheimer’s. Although we 
have come a long way with neuroimaging methods, they are un-
able to determine Alzheimer’s disease directly. Instead, after the 
onset of symptoms, brain imaging techniques such as MRIs and 
PET scans are used to rule out other probable causes of brain 
dysfunction; such as stroke or other forms of dementia. If these 
are not indicated, a diagnosis of probable Alzheimer’s is given 
??????????????????????????????????????????????????????????????-
?????????????????????????????????????????????????????????????????
(National Institute on Aging, 2015).
???????????????????????????????????????????????????????????
?????????????? ?????????? ????????????????? ?????????????? ????
??????????????????? ???????????? ?????????????????????????????
and cause the deterioration of the brain is not yet understood. 
??????????????? ???????? ???? ????? ??????? ???? ???????? ??? ????? ????
composed and caused by defective tau proteins. Tau proteins 
are microtubule-associated proteins that are common in the 
central nervous system. In a healthy person, these tau proteins 
hold microtubules in place and keep them steady. However in 
Alzheimer’s disease the tau proteins become hyperphosphory-
lated and they cease to support the microtubules. The micro-
tubules unwind and collapse and the hyperphosphorylated tau 
??????????? ??????????????????????????????????????????????????
?????????????????????????? ????? ???????????????????????????????????
the tangles participate in the cause of Alzheimer’s disease or are 
just an effect of it (C. Bancher, 1989). However, the density of 
the tau tangles correlates with the extent of dementia and  they 
are located in the affected brain areas.  A possible mechanism 
???????????????????????????????????????????????????????????????
follows. When disrupted microtubules are abundant, the neu-
ron is weakened and it becomes unable to transmit impulses 
at a normal rate. The body’s immune system detects compro-
mised neurons and triggers apoptosis of the cells (Wang, Xia, 
Grundke-Iqbal, & Iqbal, 2013).
???? ??????????????? ????? ????????????? ?????????????????-
loid plaque. In the healthy brain, tangles and plaques are present 
in small quantities and pose no problem. It is when the beta 
amyloid amounts build up that issues arise. It is understood that 
this build up is the result of a difference between the amount 
of beta amyloid plaque that is formed and the amount that is 
removed. Beta amyloid plaque is formed by the breakdown of 
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worsen, eventually leading to a loss of cognitive function and death. The two outstanding changes in the brain associated with 
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correlate with amyloid beta accumulation in human and animal brains. The precise mechanism of action and the causation are 
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amyloid precursor protein (APP), which is present in the syn-
apses of neurons. APP is present all over the brain and is thought 
to perform a function relating to neuron growth (Thinamaran 
& Koo, 2008).  APP is broken down by several enzymes known 
as alpha, beta, and gamma secretase. When amyloid precursor 
protein is broken down by a combination of alpha and gamma 
secretase it forms a protein called ?APP which may have effects 
that protect the brain (Krishnaswamy, Verdile, Groth, Kanyenda, 
& Martins, 2009). However, when beta secretase takes the place 
of alpha secretase, it forms beta amyloid, which is sticky and in-
soluble allowing it to form plaques. The process of how beta am-
yloid plaque is removed from the brain is not fully understood 
but it could be performed in a variety of ways including protein 
transport through the blood or destruction by enzymes, such 
as insulin. Beta amyloid plaque is neurotoxic and it can inhibit 
synapse formation, disrupt mitochondrial action, contribute to 
???????????????????????????????????????????????????????????????
??????????????????? ??? ??????????????????????????? ??????????????
???????? ???????????? ???????? ? ???????? ????? ???????????????
tangles and tau proteins in the onset of age related Alzheimer’s. 
Other diseases have tangles but Alzheimer’s disease is associat-
ed with plaque formation. (Lee, Goedert, & Trojanowski, 2001) 
Additionally, it is supposed that beta amyloid plaque forms earli-
er in the progression of Alzheimer’s disease and contributes to 
??????????????????????????????????????????????????????? ????????????
????? ????? ???????? ??????? ??? ????????? ??????????? ??????? ??? ????
????????????????????????????????????????????????????????????????????????????????? ???????????????????????? 
???????? ?????????????????????????????????????????????????????????????????????????????
???????????????????????????????? ???
of a patient diagnosed with Alzheimer 
??????????????????????????????????
plaque formations within the neuropil 
????????????????????????????????????????
tangles in the Hippocampus of 
a person with Alzheimer-related 
??????????????????????????????????
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pathogenesis of Alzheimer’s is called the “amyloid hypothesis” 
(Burnham & Thornton, 2015).
There are two forms of Alzheimer’s and they have inherently 
different causes. Early onset Alzheimer’s is when Alzheimer’s 
disease occurs to people under 65. Most people with this form 
of the disease have a mutation in one of three genes, APP, PSEN 
1, and PSEN 2. These mutations run in families and create a 
disposition to suffer from early onset Alzheimer’s. (Bird, 2015) 
This is a genetic disease but it is far less common than late 
onset Alzheimer’s disease and it accounts for about 5 percent of 
total Alzheimer’s cases. In late onset Alzheimer’s disease, there 
is also a genetic component connected with the APOE gene 
but the main risk factor is age. The older someone is, the more 
they are at risk of late onset Alzheimer’s disease. The reasons 
why age should increase risk for Alzheimer’s disease are not yet 
understood. Research is being done into the natural changes 
that occur in the body with age as possible contributors to 
Alzheimer’s disease. The age-related changes to the hypotha-
lamic/pituitary/gonadal feedback loop that regulates sex hor-
mone levels in the blood is a strong candidate for this research.
The sex hormones are produced in the context of a feed-
back loop with Gonadotropin-releasing hormone in the hy-
pothalamus and the gonadotropins, luteinizing hormone and 
follicle stimulating hormone which are released by the pituitary 
gland. In a healthy individual, Gonadotropin-releasing hormone 
is released from the hypothalamus in surges in response to in-
ternal and environmental factors. It travels to the anterior pi-
tuitary gland where it stimulates gonadotropic cells to produce 
luteinizing hormone and follicle stimulating hormone These 
hormones travel to the gonads, the testicles and the ovaries, 
and they stimulate them to release testosterone and estrogen 
respectively. To prevent too much of these hormones from being 
????????????????????????????????????????????????????????????????
negative feedback that discourages the further production of 
GnRH by the hypothalamus. However, with advancing age the 
process changes. Testosterone levels fall gradually in men, and in 
women estrogen drops rapidly after menopause. Without the 
negative feedback of the endpoint, gonadotropin levels tend to 
rise, although this is not true in all cases. (Jones, 2012)
For many years it was thought that the lowered levels of 
testosterone and estrogen that come with age were involved in 
the cause of Alzheimer’s. It was assumed that these hormones 
had neuroprotective properties and their absence allowed 
Alzheimer’s disease to creep in. However, it was found that 
giving testosterone or estrogen directly did not lower risk for 
Alzheimer’s disease and in fact raised it. (Manly, et al., 2000) 
Since supplementing with testosterone/estrogen was not useful 
in preventing or understanding Alzheimer’s disease, the next 
logical step was to look at the heightened levels of gonado-
tropins that relate to the lower sex hormone levels. However, 
even in this case distinctions must be made.
Luteinizing hormone and follicle stimulating hormone are 
both released by the anterior pituitary gland in response to 
Gonadotropin-releasing hormone. Structurally, LH and FSH 
are similar. They both are heterodimeric glycoproteins and are 
composed of an alpha and beta subunit. The alpha subunit of lu-
teinizing hormone and follicle stimulating hormone are identical, 
however, the beta subunit is different and this is how they con-
nect to different receptors and have a different scope of action. 
In men, luteinizing hormone is released throughout the day and 
stimulates Leydig cells to produce testosterone. Follicle stimu-
lating hormone stimulates Sertoli cells which help sustain the 
??????????????????????????????????????????????????????????????????????????????????????????????????????
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maturing sperm cells. In women, follicle stimulating hormone 
stimulates growth of the follicle in the ovary which increases 
production of estradiol and estrogen. When the follicle is ma-
ture, there is a critical level of estrogen that is reached and that 
stimulates a surge in luteinizing hormones, which in turn causes 
the release of the egg from the follicle. LH and FSH are different 
in both structure and function and how they interact with am-
????????????????????????????????????????????????????????????????
between luteinizing hormone and the levels of beta amyloid 
plaque in the brain and this will be presented and evaluated.
If increased levels of luteinizing hormone contribute to 
Alzheimer’s disease, it would be useful to have an explanation 
for how it does so. The presence of luteinizing hormone in the 
brain is not expected as it is not lipid soluble and in theory can-
not cross the blood brain barrier. However luteinizing hormone 
is found in the brain and it has been found that LH can pass 
through this barrier in small amounts (Lukacs, Hiatt, Lei, & Rao, 
1995). It is also a possible that luteinizing hormone is synthe-
sized in the brain itself. LH receptors are found not only in the 
gonads but also in the brain which would imply that it may be 
active there as well. It may be that signals which are mediated by 
luteinizing hormone receptors affect the processing of APP and 
?????????????????????????????????????????????????????????????????
than alpha secretase. This would result in a higher level of beta 
amyloid plaque formed relative to ?APP and could trigger a cas-
cade of beta amyloid plaque buildup and ultimately Alzheimer’s 
disease. 
Possibility of Treatment
Since elevated levels of luteinizing hormone could be a fac-
tor in the pathogenesis of Alzheimer’s disease, they are also a 
target for prevention or reversal of the disease. By lowering 
levels of luteinizing hormone in the blood, the contribution lu-
teinizing hormone is making to the disease could be negated. 
A potential medicine that could be effective in this therapy is 
leuprolide acetate. Leuprolide, also called leuprorelin, is a syn-
thetic hormone that is currently prescribed under the name 
Lupron to treat prostate cancer, sex hormone imbalance, 
and even less serious issues such as early onset of puberty 
(World Health Organization, 2015). Leuprolide acts as an ag-
onist to the Gonadotropin-releasing hormones. It binds to the 
Gonadotropin-releasing hormone receptors in the pituitary 
gland and interrupts their stimulation. This results in a downreg-
ulation of luteinizing hormone and follicle stimulating hormone. 
Leuprolide is delivered by injection and it can be self-adminis-
tered after training. It has mild short-term side effects including 
dizziness, itching, and headaches. As a long-term treatment, it 
can weaken bone density (Norsigian, 2005). However, with the 
research we currently have, the long-term side effects do not 
????? ?????? ????? ???????????? ????????????????????????? ????????
the pathology of Alzheimer’s. The effectiveness of Leuprolide as 
a treatment to lower luteinizing hormone levels, improve cogni-
tion, and prevent or even reverse the accumulation of amyloid 
plaque will be discussed in this paper.
Methods
All the information that was used in this article was gathered 
from online using the Touro Library search and Google Scholar. 
The search terms that were used were leuprolide acetate, le-
uprorelin, Alzheimer’s disease, beta amyloid plaque, luteinizing 
hormone, gonadotropins, hormone, gonadotropin releasing 
hormone. The articles were drawn from accepted and peer re-
???????????????????????????????????????????????????????? ????????
that were used were selected from dependable sources, govern-
????????????????????????????????????????
Discussion:  
Alzheimer’s Disease and Heightened Luteinizing 
Hormone Levels in Humans
In one study, plasma samples were taken from 284 patients seen 
at a tertiary care center and measured for concentrations of lu-
teinizing hormone and follicle stimulating hormone. The patients 
were divided into three groups, 134 with probable Alzheimer’s 
disease, 45 with frontal temporal dementia (FTD), and 105 cog-
nitively normal controls. The researchers logged each patient’s 
score on the Mini-Mental State Examination (MMSE) to mea-
sure severity of dementia. They recorded length of sickness, the 
sex and age of the subjects, and, in the case of women, if they 
were taking an estrogen supplement. It was found that there 
was no relationship between follicle stimulating hormone lev-
els in men between the controls and the Alzheimer’s disease 
group and although there was one with luteinizing hormone, 
??????????? ??????????????????????????? ???? ????????? ? ????????
?????????????????????????????????????????????????????????????
????????????????????????????????????????????????????????????????
compared to the controls after a univariate analysis (Figure 4)
In women who were not taking any form of estrogen, this 
study found elevated levels of luteinizing hormone and follicle 
stimulating hormone compared to controls. The luteinizing hor-
mone levels were higher in the Alzheimer’s group compared 
to the frontotemporal dementia group which indicates that 
they were not just an effect of dementia or brain deteriora-
?????? ??????????????????????????????????????????????????????
were taking estrogen but that is not unexpected, considering 
that estrogen is part of a negative feedback loop that limits lu-
teinizing hormone production. Within the men, there was no 
difference found between the FTD group and the Alzheimer’s 
disease group. It is possible that this is due to the small sample 
size. An important part of this study found that in estrogen free 
women, there was a connection between elevated levels of go-
nadotropins and Alzheimer’s disease.
In a previous study by the same authors, a difference was 
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found for men as well. The study tested 40 males who were 
diagnosed with Alzheimer’s disease in a long-term care center 
and compared them to 29 controls.  The study found that the 
?????? ????? ???????? ????????? ????? ????????????? ??????? ??? ?????
luteinizing hormone and follicle stimulating hormone levels rela-
tive to the control group. (Bowen, Isley, & Atkinson, 2000).
In another study, 585 normal and healthy men between the 
ages of 70 and 87 years were tested for luteinizing levels to try 
???????????????????????????????????????????????????????????????-
?????????????????????????????????????????????????????????????
in previous studies, this correlation had not been demonstrated 
for men as strongly as in women. The study found that higher 
levels of luteinizing hormone were related to worse perfor-
mance on CVLT-II which is a test for immediate recall (Hyde, 
et al., 2010).
In an even larger study that evaluated the effects of elevat-
ed levels of gonadotropins on cognition in elderly women, 649 
women without dementia were given cognitive testing and 
blood samples were taken. Plasma levels of luteinizing hormone, 
estradiol, follicle stimulating hormone, and beta amyloid were 
recorded. The study found that elevated levels of luteinizing hor-
mone were associated with worse cognitive performance and 
depression (Rodrigues, et al., 2008).
In the Australian Imaging Biomarkers and Lifestyle study of 
aging, more than 1000 people were assembled to conduct a lon-
gitudinal study to aid understanding Alzheimer’s beginnings and 
progression. The subjects were given full cognitive evaluation, 
their blood was analyzed and many of them had their brains 
imaged by MRI machines and various brain imaging technology. 
The participants were grouped by cognitive issues. The categories 
were healthy, subjective memory impairment, mildly impaired, and 
Alzheimer’s patients. It was not the primary focus of the study to 
??????????????????????????????????????????????????????????????????
that was taken was tested for it amongst other things. Some re-
searcher reviewed the data with an eye on luteinizing hormone 
and it was found that increased levels of luteinizing hormone in 
the blood were correlated with beta amyloid presence in the 
brain as measured by imaging techniques. This was only found in 
the subjective group, which suggests that the most important link 
between luteinizing hormone and beta amyloid plaque is in the 
preliminary stages of Alzheimer’s disease (Ellis, et al., 2009).
Animal Trials
In studying disease pathology, and possible treatment options, it 
is not always possible to use humans as some potential treat-
ments may have negative side effects, it is therefore better to 
?????????????????????????????????? ???????????????????????????-
cause of their biological similarities to humans. Some research-
ers have studied ties between luteinizing hormone, beta amyloid 
plaque, and cognition in transgenic mice that have genes that 
lead to Alzheimer’s disease development. To test for cognition in 
mice, researchers use a test known as ‘spontaneous alternation’. 
It is a behavioral test which tests spatial learning and memory. In 
this test, the animal is put in the center of a maze and can move 
freely. Spatial memory is tested by observing whether the mouse 
remembers which arms of the maze it has already explored. It 
???????????????????????????????????????????????????????????????
factors such as attention or sensory stimuli (Hughes, 2004).
In a study of 21, one month old transgenic Tg2576 mice, the 
effects of high luteinizing hormone levels in the mice on amyloid 
beta plaque deposition were tested. The animals were bred to 
over-express human APP to ensure that there would be beta am-
yloid plaque buildup. In this breed in general, beta amyloid plaque 
??????????????????????????????????????????????????????? ???????
are 10 months old, the level of beta amyloid plaque is enough to 
form an accumulation. The mice were randomly split into two 
groups. One was a control group that received saline solution 
and the second group received leuprolide.  The mice were tested 
with mazes to examine spontaneous alternation and their blood 
levels of luteinizing hormone were assayed to evaluate the effects 
of leuprolide. The brains were sliced on the sagittal plane and pre-
????????????????????????????????????????????????????? ????????
????? ???????????? ??????????????? ???????????????????????????????
lower levels of luteinizing hormone compared to the saline group 
especially 3 months after the treatment. The leuprolide-treated 
mice performed better on the maze task than the control group. 
Additionally, the leuprolide-treated mice had lower levels of beta 
amyloid plaque and this correlated with the improved cognition 
(Casadesus, et al., 2006).
Mice which were bred to have an elevated level of amyloid 
beta precursor proteins had higher levels of luteinizing hor-
mone and faster cognitive decline. The group that was treated 
with leuprolide, to help lower luteinizing hormone levels, had 
?????????????????????? ?????????????????????????????????????????????
??????????????????????????????????????????????????????????????????
??????????? ????????????????????????????????????????????????????
??????????????????????????????????????????????????????????????
????????????????????????????????????????????????????????????
????????????????????????????????
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less beta amyloid plaque deposition and better cognitive perfor-
mance than the controls. 
In another study done with mice, Tg2576 mice that were bred 
to express the human amyloid precursor gene were crossed 
with mice that had the genes for luteinizing hormone receptors 
removed, so that they couldn’t use luteinizing hormone. There 
were two control groups. One of the control groups were APP 
expressing mice that were not crossbred. A second control 
group was mice that had luteinizing hormone receptors and did 
not express the human APP gene. Finally, a group of normal mice 
was a third control.  The animals were raised for 16 months, 
??????????? ???? ????? ?????? ??????? ????? ?????????????? ? ??????
software was used to compare the beta amyloid concentrations 
??????????????????????????????????????? ???????????????????????
???????????????????????????????????????????????????????????????
in the mice which had luteinizing hormone receptor knockout 
compared to the mice with APP that did have luteinizing hor-
mone receptors. (Lukacs, Hiatt, Lei, & Rao, 1995) 
??????????????????????????????????????????????????????????
elevated luteinizing hormone levels and Alzheimer’s disease or 
beta amyloid plaque deposition. If luteinizing hormone is a part 
of the cause of Alzheimer’s, it presents exciting treatment possi-
bilities through the lowering of luteinizing hormone levels espe-
cially to prevent deterioration in those at risk for Alzheimer’s. A 
promising candidate for a medication that can accomplish this 
safely is leuprolide. 
Leuprolide as a Treatment for Alzheimer’s Disease
Leuprolide interferes with GnRH in humans and therefore 
brings about lower levels of luteinizing hormone. It is not an 
approved treatment for Alzheimer’s disease as of now. However, 
since leuprolide is an approved treatment for prostate cancer, 
some studies have observed the effect that leuprolide has had 
on Alzheimer’s disease in the patients using it for other rea-
sons. Clinical trials are currently underway to test this possi-
bility under the code ALADDIN which is an abbreviation for 
Antigonadotropin-Leuprolide in Alzheimer’s Disease Drug 
Investigation
One study of the impact of leuprolide on Alzheimer’s disease 
in patients with prostate cancer was done in 2010. The study 
looked at the risk of death by Alzheimer’s disease in 6,647 men 
who were treated for prostate cancer. In the study, 1700 men 
who were treated with leuprolide were compared to 4,947 
controls who were treated using other drugs that do not limit 
luteinizing hormone production. After 4 years of follow up, 81 
of the group in the study had died from Alzheimer’s disease. 
Those who died of Alzheimer’s were found to be from the con-
trol group rather than from the group of patients who took 
leuprolide for at least 4 months (D’Amico, Braccioforte, Moran, 
& Chen, 2010).
The results were that Leuprolide can aid in slower regres-
sion and improved cognition in Alzheimer’s patients. Voyager 
Pharmaceuticals is not currently pursuing further research into 
Lupron and most likely will not do so in the future as it declared 
bankruptcy in 2012. In an interview for medicalresearch.com, 
Richard Bowen cited lack of marketability to account for the 
dearth in leuprolide research. “Unfortunately, there is no intel-
lectual property protection for this treatment making it unlikely 
that a pharmaceutical company will take the lead.” (R. Bowen). 
??????????????? ?????????????????????????? ????? ?????????????????
the funding will come from a government the government or 
foundation, and leuprolide research will be continued. 
Conclusion
Alzheimer’s disease is a common debilitating disease that is 
one of the main leading causes of death in the United States. 
One of the main changes detected in the brain of a patient 
with Alzheimer’s disease is beta amyloid plaque. These plaques 
can only be detected after death, upon autopsy. Studies have 
shown that a rise in luteinizing hormone is linked to increased 
beta amyloid plaque and Alzheimer’s. Studies have been done 
to lower Gonadotropin-releasing hormone levels through the 
treatment of Leuprolide acetate, a Gonadotropin-releasing hor-
?????????????? ?????????????????????????????????????????????????
is therefore on hold for the time being; however, the possibility 
of this treatment for Alzheimer’s disease is somewhat promising 
and deserving of more research. 
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